HealthEquity (NASDAQ:HQY) Issues FY25 Earnings Guidance

HealthEquity (NASDAQ:HQY) updated its FY25 earnings guidance on Monday. The company provided earnings per share guidance of 3.08-3.16 for the period, compared to the consensus earnings per share estimate of $3.12. The company issued revenue guidance of $1.185-1.195 billion, compared to the consensus revenue estimate of $1.18 billion. HealthEquity also updated its FY 2025 guidance to 3.080-3.160 EPS.

Wall Street Analyst Weigh In

Several brokerages recently commented on HQY. Barrington Research boosted their price target on HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. JMP Securities boosted their price target on HealthEquity from $105.00 to $107.00 and gave the stock a “market outperform” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft boosted their price target on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Royal Bank of Canada boosted their price target on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Mizuho began coverage on HealthEquity in a research report on Wednesday, December 4th. They set an “outperform” rating and a $126.00 price target for the company. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.71.

HealthEquity Stock Performance

NASDAQ HQY opened at $95.39 on Wednesday. The stock has a market cap of $8.33 billion, a PE ratio of 79.49, a P/E/G ratio of 1.57 and a beta of 0.55. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity has a twelve month low of $62.10 and a twelve month high of $105.82. The stock has a fifty day simple moving average of $93.11 and a 200-day simple moving average of $83.90.

Insider Transactions at HealthEquity

In related news, Director Robert W. Selander sold 8,250 shares of the stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the transaction, the director now owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. This represents a 13.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frank Corvino sold 1,039 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total value of $99,847.90. Following the transaction, the director now directly owns 3,784 shares in the company, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,536 shares of company stock worth $884,517. 2.20% of the stock is currently owned by company insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.